About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Casodex - Nolvadex Combination | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT00637871

Casodex - Nolvadex Combination

This study looks at the relationship in the dose of nolvadex and the incidence of gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with Casodex. The aim of the st...

Lead sponsor: AstraZeneca•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Age

All ages

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•Subjects with adenocarcinoma of the prostate gland but with no evidence of distant metastasis. The stage of disease should be T1-T4, any N, M0 confirmed histologically or cytologically
•Subjects in need of immediate hormonal therapy.
•PSA equal or above 4 ng/ml

Exclusion Criteria

•Presence of gynaecomastia and/or breast pain at screening visit
•Any previous endocrine therapy for prostate cancer other than neoadjuvant LHRH therapy prior to primary therapy of curative intent.
•Current use, or within the previous 6 months, of any medication known to have a high risk of causing gynaecomastia .
•Previous mastectomy or radiation to chest wall

Related studies

Selecting Hypoxic Tumours for Treatment Modification

NCT06787053 · Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer

Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE)

NCT07580196 · Prostate Cancer

RECRUITINGPhase 1/2

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT06616155 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more

DESTINY-PANTUMOUR04

NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more

Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

NCT07181122 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 24, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment—

Start dateNov 2002

Last updatedJan 24, 2011

Condition

Gynaecomastia Prostate Cancer

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 24, 2011Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions